Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Buy
65
LRCX Quote, Financials, Valuation and Earnings
Last price:
$80.28
Seasonality move
:
8.03%
Day range:
$78.31 - $82.83
52-week range:
$68.87 - $113.00
Dividend yield:
1.09%
P/E ratio:
25.60x
P/S ratio:
6.67x
P/B ratio:
12.03x
Volume:
19.1M
Avg. volume:
11.3M
1-year change:
4.08%
Market cap:
$101.9B
Revenue:
$14.9B
EPS (TTM):
$3.09
Analysts' Opinion
-
Consensus RatingLam Research has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $92.01, Lam Research has an estimated upside of 16.15% from its current price of $79.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 5.33% downside risk from its current price of $79.22.
Fair Value
-
According to the consensus of 29 analysts, Lam Research has 16.15% upside to fair value with a price target of $92.01 per share.
LRCX vs. S&P 500
-
Over the past 5 trading days, Lam Research has overperformed the S&P 500 by 0.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lam Research does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lam Research has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Lam Research reported revenues of $4.2B.
Earnings Growth
-
Lam Research has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Lam Research reported earnings per share of $0.86.
Enterprise value:
100.8B
EV / Invested capital:
--
Price / LTM sales:
6.67x
EV / EBIT:
20.95x
EV / Revenue:
6.47x
PEG ratio (5yr expected):
5.06x
EV / Free cash flow:
20.84x
Price / Operating cash flow:
21.50x
Enterprise value / EBITDA:
19.48x
Gross Profit (TTM):
$7.4B
Return On Assets:
21.61%
Net Income Margin (TTM):
26.02%
Return On Equity:
49.11%
Return On Invested Capital:
30.64%
Operating Margin:
30.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $18B | $15.8B | $15.6B | $3.5B | $4.2B | |
| Gross Profit | $8.2B | $7.1B | $7.4B | $1.7B | $2B | |
| Operating Income | $5.7B | $4.5B | $4.5B | $1B | $1.3B | |
| EBITDA | $6B | $5B | $5.2B | $1.2B | $1.4B | |
| Diluted EPS | $3.49 | $2.95 | $3.09 | $0.67 | $0.86 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.3B | $11.1B | $13.6B | $13B | $13.5B | |
| Total Assets | $15.1B | $15.6B | $18.7B | $18.5B | $19.5B | |
| Current Liabilities | $3.4B | $3.4B | $5.1B | $4.2B | $5.3B | |
| Total Liabilities | $9.6B | $9.7B | $11.3B | $10.5B | $11.1B | |
| Total Equity | $5.4B | $5.8B | $7.4B | $8B | $8.5B | |
| Total Debt | $5.8B | $5B | $5B | $5B | $5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3.8B | $4.9B | $5.3B | $951.2M | $1.6B | |
| Cash From Investing | -$112.2M | -$481.4M | -$406.5M | -$74.7M | -$110.6M | |
| Cash From Financing | -$3.5B | -$3.8B | -$3.9B | -$1.3B | -$1.3B | |
| Free Cash Flow | $3.3B | $4.5B | $4.8B | $874.2M | $1.5B | |
LRCX
Sector
Market Cap
$101.9B
$115.1M
Price % of 52-Week High
70.11%
67.62%
Dividend Yield
1.09%
0%
Shareholder Yield
3.84%
0.91%
1-Year Price Total Return
4.08%
-5.01%
Beta (5-Year)
1.455
0.916
Dividend yield:
1.09%
Annualized payout:
$0.80
Payout ratio:
25.87%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$76.51
200-day SMA
Sell
Level
$85.61
Bollinger Bands (100)
Buy
Level
73.02 - 80.04
Chaikin Money Flow
Buy
Level
237.7M
20-day SMA
Buy
Level
$74.75
Relative Strength Index (RSI14)
Buy
Level
60.76
ADX Line
Buy
Level
23.21
Williams %R
Neutral
Level
-31.2284
50-day SMA
Buy
Level
$74.92
MACD (12, 26)
Buy
Level
0.47
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
574.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.1579)
Buy
CA Score
(Annual)
Level (0.6924)
Buy
Beneish M-Score
(Annual)
Level (-2.819)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-2.1207)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
Stock Forecast FAQ
In the current month, LRCX has received 15 Buy ratings 14 Hold ratings, and 0 Sell ratings. The LRCX average analyst price target in the past 3 months is $92.01.
-
Where Will Lam Research Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lam Research share price will rise to $92.01 per share over the next 12 months.
-
What Do Analysts Say About Lam Research?
Analysts are divided on their view about Lam Research share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lam Research is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Lam Research's Price Target?
The price target for Lam Research over the next 1-year time period is forecast to be $92.01 according to 29 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is LRCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lam Research is a Buy. 15 of 29 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LRCX?
You can purchase shares of Lam Research via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lam Research shares.
-
What Is The Lam Research Share Price Today?
Lam Research was last trading at $80.28 per share. This represents the most recent stock quote for Lam Research. Yesterday, Lam Research closed at $79.22 per share.
-
How To Buy Lam Research Stock Online?
In order to purchase Lam Research stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Why Is Stanley Druckenmiller Buying Citigroup?
As recently as 2020, few analysts could have predicted that…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
NUTX alert for Jan 17
Nutex Health [NUTX] is up 2.83% over the past day.
Buy
53
QMCO alert for Jan 17
Quantum [QMCO] is down 15.61% over the past day.
Sell
34
NGVT alert for Jan 17
Ingevity [NGVT] is up 1.31% over the past day.
